# Hartmut Döhner

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/hartmut-dohner/

## Facts

| Field | Value |
| --- | --- |
| Citations | 116,278 |
| Field | Acute Myeloid Leukemia Research |
| h-index | 147 |
| i10-index | 620 |
| Last Known Institution | Universität Ulm |
| OpenAlex ID | https://openalex.org/A5089395073 |
| ORCID iD | https://orcid.org/0000-0003-2116-5536 |
| Works | 1,400 |

## Researcher papers

- [Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial](https://scholariq.org/papers/addition-of-rituximab-to-fludarabine-and-cyclophosphamide-in-patients-with/)
- [<i>TP53</i> Mutation and Survival in Chronic Lymphocytic Leukemia](https://scholariq.org/papers/i-tp53-i-mutation-and-survival-in-chronic-lymphocytic-leukemia/)
- [Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial](https://scholariq.org/papers/gene-mutations-and-treatment-outcome-in-chronic-lymphocytic-leukemia-results/)
- [Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group](https://scholariq.org/papers/bendamustine-in-combination-with-rituximab-for-previously-untreated-patients/)
- [Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up](https://scholariq.org/papers/monoallelic-tp53-inactivation-is-associated-with-poor-prognosis-in-chronic/)
- [Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group](https://scholariq.org/papers/bendamustine-combined-with-rituximab-in-patients-with-relapsed-and-or-refractory/)
- [Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial](https://scholariq.org/papers/allogeneic-stem-cell-transplantation-provides-durable-disease-control-in-poor/)
- [Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial](https://scholariq.org/papers/detailed-analysis-of-p53-pathway-defects-in-fludarabine-refractory-chronic/)
- [miR-34a as part of the resistance network in chronic lymphocytic leukemia](https://scholariq.org/papers/mir-34a-as-part-of-the-resistance-network-in-chronic-lymphocytic-leukemia/)

## Researcher topics

- [Acute Myeloid Leukemia Research](https://scholariq.org/topics/acute-myeloid-leukemia-research/)
- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)
- [Chronic Myeloid Leukemia Treatments](https://scholariq.org/topics/chronic-myeloid-leukemia-treatments/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Myeloproliferative Neoplasms: Diagnosis and Treatment](https://scholariq.org/topics/myeloproliferative-neoplasms-diagnosis-and-treatment/)

## Researcher university

- [Universität Ulm](https://scholariq.org/institutions/universitat-ulm/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.